Loqtorzi
What Loqtorzi is used for
Loqtorzi, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. Loqtorzi, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Loqtorzi
- Active substance
- toripalimab
- Disease area
- Nasopharyngeal Carcinoma; Esophageal Squamous Cell Carcinoma
- Medicine group
- Antineoplastic agents
- ATC code
- L01FF13
- Marketing authorisation holder
- Topalliance Biosciences Europe Limited
- Authorised in the EU since
- 2024
Official information
In the USA
Same active substance: Loqtorzi
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Loqtorzi used for?
Loqtorzi, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. Loqtorzi, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
What is the active substance in Loqtorzi?
Loqtorzi contains toripalimab.
Who makes Loqtorzi?
The EU marketing authorisation holder is Topalliance Biosciences Europe Limited.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU